European Medical Journal (Apr 2021)

Rifampicin-Induced Thrombocytopenia: A Case Report and Short Review of the Literature

  • Epameinondas Koumpis,
  • Konstantina Papathanasiou,
  • Ioannis Papakonstantinou,
  • Iliana Tassi,
  • Anastasia Serpanou,
  • Eleni Kapsali,
  • Eleftheria Hatzimichael

DOI
https://doi.org/10.33590/emj/20-00193

Abstract

Read online

Thrombocytopenia may be associated with a variety of conditions and risks depending on its severity, ranging from mild epistaxis to life-threating bleeding. Many drugs or herbal remedies can cause thrombocytopenia by either inhibiting platelet production and/or enhancing their destruction from the peripheral blood mediated via an immunological mechanism implicating drug-dependent antibodies. The latter entity is called drug-induced immune thrombocytopenia: a life-threatening, under-recognised condition, which is often a diagnostic challenge. Rifampicin is a widely used, well-tolerated, and effective bactericidal drug. Adverse events, except for gastrointestinal effects, headache, skin rash, and pruritus, are uncommon. The authors herein report on a patient with isolated thrombocytopenia with a recent medical history of brucellosis on rifampicin and doxycycline. Thrombocytopenia was proved to be rifampicin-induced. Also presented is a short review of the literature on this rare subject, which should be of great importance to clinicians.